INTS
Intensity Therapeutics, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
4.86
▼ 0.02 (0.41%)
MARKET · —
Price
Open
4.85
Prev close
4.88
Day high
4.89
Day low
4.53
Volume
20.05K
Market cap
—
P/E (TTM)
—
52W range
3.51 – 43.50
Trailing performance
Returnvs SPY
1W
+22.73%
+24.1%
1M
+9.71%
+6.0%
3M
+3.18%
+0.1%
6M
-17.06%
-28.1%
YTD
-52.59%
-64.9%
1Y
-35.20%
-55.2%
3Y
-96.63%
-170.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.29
+13.26% from price
SMA 20
4.28
+13.54% from price
SMA 50
4.31
+12.82% from price
SMA 100
4.62
+5.25% from price
SMA 200
6.97
-30.28% from price
EMA 12
4.38
+11.01% from price
EMA 26
4.35
+11.74% from price
EMA 50
4.44
+9.57% from price
RSI (14)
65.5
Neutral
MACD (12,26,9)
0.03
Hist 0.07
ATR (14)
0.28
5.74% of price
Realised vol 30D
61.2%
Annualised
Bollinger upper
4.77
20, 2σ
Bollinger lower
3.79
20, 2σ
50 / 200 cross
Death
4.31 vs 6.97
Trend bias
Below 200
-30.28%
Risk profile
Beta vs SPY
-1.64
Less volatile than market
Correlation to SPY
-0.05
Largely independent
Realised vol 30D
61.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-89.0%
Peak to trough
Max drawdown 5Y
-98.5%
Peak to trough
ATR 14
0.28
5.74% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 11d ago
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
PR Newswire · 11d ago
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
PR Newswire · 18d ago
Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
PR Newswire · 38d ago
Intensity Therapeutics Resumes Dosing in Phase 2 Trial for Investigational Cancer Therapy in Switzerland
MT Newswires · 38d ago
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
PR Newswire · 38d ago
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
PR Newswire · 52d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.